News
Talecris Celebrates 20 years of Prolastin
Talecris Biotherapeutics, Inc. is celebrating the 20th anniversary of the launch of Prolastin®, it’s leading augmentation therapy for Alpha-1.
Prolastin was the first plasma-derived AAT augmentation therapy to receive approval from the U.S. Food and Drug Administration (FDA). Approved in December 1987, and launched in February 1988, Prolastin was the first FDA-approved product for AAT augmentation therapy for Alpha-1 patients and remained so for nearly 17 years.
“Talecris has been committed to increasing our understanding of Alpha-1 and its treatment,” said John W. Walsh, Chief Executive Officer and Co-Founder of the Alpha-1 Foundation. “Moreover, their significant contributions to the Alpha-1 community have allowed us to identify thousands of individuals with this genetic condition and increase awareness of Alpha-1, allowing families to learn to prevent this disease and to receive effective treatment when appropriate.”
